We are proud to be part of the newly funded PRIME NEXT-GEN project, an ambitious interdisciplinary initiative dedicated to advancing precision medicine for obesity, type 2 diabetes and chronic inflammatory diseases.
These conditions frequently coexist and share complex biological, environmental and social determinants. PRIME NEXT-GEN brings together expertise in health sciences, artificial intelligence, and the social sciences and humanities to better understand these links and improve patient care.
The project will draw on large, clinically and socio-economically characterised cohorts, together with biobanks analysed using next-generation omics technologies. Its objective is to identify more homogeneous patient subgroups, known as endotypes, based on underlying biological mechanisms — with particular attention to meta-inflammation.
Through these advances, PRIME NEXT-GEN aims to establish a more mechanism-based classification of metabolic and inflammatory diseases. This work could support more personalised care pathways, reduce complications and improve quality of life for patients.
As part of the project, we will contribute our expertise in artificial intelligence for the analysis of complex, multimodal health data. We will also help assess the fairness of AI-based approaches and their acceptability among patients and healthcare professionals.
Coordinators: David Launay, Professor and Hospital Practitioner; Amélie Bonnefond, Inserm Research Director
Duration: 4 years
Funding: €3.2 million
